

William R Gwin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/628860/publications.pdf>

Version: 2024-02-01

15
papers

489
citations

933447

10
h-index

1199594

12
g-index

16
all docs

16
docs citations

16
times ranked

756
citing authors

#	ARTICLE	IF	CITATIONS
1	An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. <i>Breast Cancer Research</i> , 2013, 15, R85.	5.0	120
2	Vaccine Therapies for Cancer: Then and Now. <i>Targeted Oncology</i> , 2021, 16, 121-152.	3.6	90
3	Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. <i>Clinical Cancer Research</i> , 2017, 23, 5066-5073.	7.0	62
4	Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. <i>Clinical Cancer Research</i> , 2019, 25, 2725-2736.	7.0	50
5	Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio. , 2020, 8, e001662.		28
6	Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity. , 2022, 10, e003717.		27
7	Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy. <i>Onc Immunology</i> , 2017, 6, e1264563.	4.6	23
8	Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors. <i>Communications Biology</i> , 2020, 3, 226.	4.4	18
9	Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition. <i>Onc Immunology</i> , 2017, 6, e1315495.	4.6	17
10	<i>In Vivo</i> Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior. <i>Clinical Cancer Research</i> , 2017, 23, 7531-7542.	7.0	15
11	Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. <i>Breast Cancer Research</i> , 2018, 20, 90.	5.0	14
12	Pertuzumab Protects the Achilles' Heel of Trastuzumab + Emtansine. <i>Clinical Cancer Research</i> , 2014, 20, 278-280.	7.0	13
13	CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 365-372.	2.3	8
14	Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis. <i>Cancer Research</i> , 2022, 82, PD8-01-PD8-01.	0.9	4
15	Use of the TLR2 ligand polysaccharide krestin to maximize conventional cancer therapy. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017, 2, 133-135.	0.6	0